The Camp Lejeune water contamination litigation continues to move forward on multiple fronts as we enter the first quarter of 2026, though progress remains slower than many veterans and their families had hoped.
Elective Option Program
As of early 2026, the Camp Lejeune litigation includes over 3,700 federal lawsuits filed in the Eastern District of North Carolina and more than 409,000 administrative claims filed with the U.S. Department of the Navy (DON). DON is continuing to process claims under its Elective Option (EO) settlement program, which was initially announced as offering an expedited path to compensation for claimants diagnosed with one of nine qualifying conditions:
- Tier 1: Kidney Cancer, Liver Cancer, Non-Hodgkin’s Lymphoma, Leukemias, and Bladder Cancer
- Tier 2: Multiple Myeloma, Parkinson’s Disease, Kidney Disease/End Stage Renal Disease, and Systemic Sclerosis (Systemic Scleroderma)
To date, the government has paid approximately $530 million through the EO program, with individual settlements ranging from $100,000 to $550,000 depending on the condition and duration of exposure. However, as the EO program progressed, the DON began to apply a condition to all EO claims: the qualifying diagnosis or treatment must have occurred at least two years after first exposure and no more than thirty-five years after last exposure to the contaminated water at Camp Lejeune. This strict timing window has disqualified a significant number of otherwise eligible claimants from the EO program, as only about 64,000 of the over 400,000 administrative claims are estimated to qualify under these new stricter EO criteria. Discussions over the use and elimination of these criteria are ongoing.
A Global Settlement Framework is Still Pending
In mid-2024, the court appointed two Settlement Masters to develop a broader global settlement framework that would address all timely administrative claims beyond the narrow EO criteria. A status report filed in 2025 projected that a resolution plan could be in place by the end of 2025.
As of March 2026, no details of a completed global settlement plan have been made public, and there is no publicly announced timeline for rollout. However, the Settlement Masters have begun circulating claimant survey forms to approximately 2,400 randomly selected claimants to help create parameters for a settlement matrix. While no final matrix has been filed, this groundwork suggests that a draft framework could emerge in 2026, although the DON and DOJ would need to agree to any proposed matrix.
Bellwether Trials on the Horizon
The most significant litigation development heading into 2026 is the anticipated start of bellwether trials. Twenty-five Track 1 cases focusing on bladder cancer, kidney cancer, leukemia, Non-Hodgkin’s Lymphoma, and Parkinson’s disease are expected to go to trial this year. The leukemia and NHL cases have been assigned to Judge Dever in the Eastern District of North Carolina. The outcomes of these first trials will heavily influence the value of remaining claims and could pressure the government toward more significant payments.
Dozens of pretrial motions challenging the admissibility of expert testimony have been filed by both sides and must be resolved before trials can begin. The DOJ alone filed more than 30 such motions. Plaintiffs’ attorneys have pushed back, urging the court to set trial dates. The court’s rulings on these motions will be critical, not just for the 25 bellwether cases, but for all pending claims.
What All This Means for Claimants
If you have a pending Camp Lejeune claim, the most important near-term developments to watch are whether your attorney reaches out to you either under the EO program or the settlement matrix survey. Claimants who received an EO offer should consult with their attorney about whether to accept that offer or wait until these developments unfold.
We will continue to provide updates as new developments emerge.